Published by mark itwired
Posted on September 16, 2021
ESOMAR-certified Future Market Insights (FMI) has recently published an exhaustive yet unbiased analysis of the global Gaucher and Pompe disease Enzyme Replacement Therapy (ERT) market providing insights on key growth trends through 2030.
As the global burden of genetic disorders such as Gaucher disease, Fabry disease, Pompe disease and other abnormalities rise, healthcare providers are scrambling to develop potential therapeutic approaches to offset their impacts.
According to the National Gaucher Foundation, one in every 450 people belonging to the Ashkenazi Jewish community suffer from Type-1 Gaucher disease, the most prevalent form, thereby opening up credible growth prospects for the future.
“Increasing regulatory approvals by government authorities is paving way for the entry of prominent enzyme replacement therapy providers, thus generating immense revenue prospects across promising markets,” concludes the FMI analyst.
Any Queries Regarding Report, Ask Us @ https://www.futuremarketinsights.com/ask-question/rep-gb-12771
As healthcare organization reorient their resources to fight the coronavirus pandemic, the market for Gaucher & Pompe Disease ERT experienced a substantial blip in the initial months, with treatment sessions declining significantly across several countries.
For instance, until July 2020, Spain recorded a 25% decline in enzyme replacement therapy sessions amongst people suffering from Type-1 and Type-3 Gaucher Disease respectively. This largely occurred as a consequence of rescheduling treatments at a later date.
In the United States, hospital visits to avail ERT have registered considerable decline for avoiding exposure to COVID-19 patients. As a result, patient self-administration at home have burgeoned. Furthermore, the pandemic has provided an opportunity to undertake research on lysosomal dysfunction and disease pathogenesis which would enhance clinical care.
Prominent players operating in the Gaucher & Pompe Disease ERT landscape include Shire PLC, Ultragenyx Pharmaceuticals Inc., Sigma-Tau Pharmaceuticals Inc., Pfizer Inc., Alexion Pharmaceuticals Inc., Sanofi SA, Merck KGaA, Tadeka Pharmaceuticals, AbbVie Inc. and BioMarin Pharmaceutical Inc. to name a few.
Manufacturers rely on introduction of novel technologies to advance effective ERTs for numerous genetic conditions. For instance, in October 2018, the U.S Food & Drug Administration approved Sigma-Tau Pharmaceuticals’ (Lediant Biosciences) RevcoviTM injection for treating adenosine deaminase severe combined immune deficiency (ADA-SCID).
Likewise, Sanofi SA markets the Cerezyme® ERT injections through its Genzyme subsidiary, which offers a long term efficacy to elderly and pediatric patients suffering from Type-1 Gaucher Disease, and is the only known long-term cure for the condition.
Future Market Insights, in its new report, offers an unbiased analysis of the global Gaucher and Pompe Disease ERT market, analyzing historical demand from 2015-2019 and forecast statistics for 2020-2030. The study reveals growth projections on the Gaucher and Pompe Disease ERT Market on the basis of therapeutic condition (Gaucher disease and Pompe disease), route of administration (oral and parenteral) and distribution channel (hospital pharmacies, specialty treatment pharmacies, retail pharmacies and online pharmacies) across seven prominent regions.
Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-12771
According to research conducted by Future Market Insights (FMI), the Gaucher and Pompe Disease ERT Market is expected to remain on a positive trajectory, despite encountering a blip in the initial months of COVID-19, attributed to growing incidence of lysosomal storage disorders (LSD)
The Gaucher and Pompe Disease ERT Market is growing on the back of increasing orphan drug status designation to numerous drug candidates by the FDA and growing number of collaborations and partnerships among prominent market players
Type-1 neuronopathic Gaucher disease is expected to generate maximum growth opportunities, owing to its widespread prevalence amongst patients suffering from Gaucher disease
Europe is expected to be the fastest growing and largest Gaucher and Pompe Disease ERT Market, owing to enhanced approvals by regulatory authorities to different drug candidates
The post Gaucher and Pompe Diseases Enzyme Replacement Therapy (ERT) Market Competitive Analysis, Segmentation & Forecast 2030 first appeared on Market Research Blog.
ESOMAR-certified Future Market Insights (FMI) has recently published an exhaustive yet unbiased analysis of the global Gaucher and Pompe disease Enzyme Replacement Therapy (ERT) market providing insights on key growth trends through 2030.
As the global burden of genetic disorders such as Gaucher disease, Fabry disease, Pompe disease and other abnormalities rise, healthcare providers are scrambling to develop potential therapeutic approaches to offset their impacts.
According to the National Gaucher Foundation, one in every 450 people belonging to the Ashkenazi Jewish community suffer from Type-1 Gaucher disease, the most prevalent form, thereby opening up credible growth prospects for the future.
“Increasing regulatory approvals by government authorities is paving way for the entry of prominent enzyme replacement therapy providers, thus generating immense revenue prospects across promising markets,” concludes the FMI analyst.
Any Queries Regarding Report, Ask Us @ https://www.futuremarketinsights.com/ask-question/rep-gb-12771
As healthcare organization reorient their resources to fight the coronavirus pandemic, the market for Gaucher & Pompe Disease ERT experienced a substantial blip in the initial months, with treatment sessions declining significantly across several countries.
For instance, until July 2020, Spain recorded a 25% decline in enzyme replacement therapy sessions amongst people suffering from Type-1 and Type-3 Gaucher Disease respectively. This largely occurred as a consequence of rescheduling treatments at a later date.
In the United States, hospital visits to avail ERT have registered considerable decline for avoiding exposure to COVID-19 patients. As a result, patient self-administration at home have burgeoned. Furthermore, the pandemic has provided an opportunity to undertake research on lysosomal dysfunction and disease pathogenesis which would enhance clinical care.
Prominent players operating in the Gaucher & Pompe Disease ERT landscape include Shire PLC, Ultragenyx Pharmaceuticals Inc., Sigma-Tau Pharmaceuticals Inc., Pfizer Inc., Alexion Pharmaceuticals Inc., Sanofi SA, Merck KGaA, Tadeka Pharmaceuticals, AbbVie Inc. and BioMarin Pharmaceutical Inc. to name a few.
Manufacturers rely on introduction of novel technologies to advance effective ERTs for numerous genetic conditions. For instance, in October 2018, the U.S Food & Drug Administration approved Sigma-Tau Pharmaceuticals’ (Lediant Biosciences) RevcoviTM injection for treating adenosine deaminase severe combined immune deficiency (ADA-SCID).
Likewise, Sanofi SA markets the Cerezyme® ERT injections through its Genzyme subsidiary, which offers a long term efficacy to elderly and pediatric patients suffering from Type-1 Gaucher Disease, and is the only known long-term cure for the condition.
Future Market Insights, in its new report, offers an unbiased analysis of the global Gaucher and Pompe Disease ERT market, analyzing historical demand from 2015-2019 and forecast statistics for 2020-2030. The study reveals growth projections on the Gaucher and Pompe Disease ERT Market on the basis of therapeutic condition (Gaucher disease and Pompe disease), route of administration (oral and parenteral) and distribution channel (hospital pharmacies, specialty treatment pharmacies, retail pharmacies and online pharmacies) across seven prominent regions.
Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-12771
According to research conducted by Future Market Insights (FMI), the Gaucher and Pompe Disease ERT Market is expected to remain on a positive trajectory, despite encountering a blip in the initial months of COVID-19, attributed to growing incidence of lysosomal storage disorders (LSD)
The Gaucher and Pompe Disease ERT Market is growing on the back of increasing orphan drug status designation to numerous drug candidates by the FDA and growing number of collaborations and partnerships among prominent market players
Type-1 neuronopathic Gaucher disease is expected to generate maximum growth opportunities, owing to its widespread prevalence amongst patients suffering from Gaucher disease
Europe is expected to be the fastest growing and largest Gaucher and Pompe Disease ERT Market, owing to enhanced approvals by regulatory authorities to different drug candidates
The post Gaucher and Pompe Diseases Enzyme Replacement Therapy (ERT) Market Competitive Analysis, Segmentation & Forecast 2030 first appeared on Market Research Blog.
Explore more articles in the Research Reports category
